Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

I Want To Thin Your Blood: Vampire Bat-Based Stroke Drug Trial Resumes

This article was originally published in The Pink Sheet Daily

Executive Summary

Potential safety signal in Forest/PAION’s desmoteplase study no longer spooks data monitoring committee.

You may also be interested in...



Forest/Paion’s Desmoteplase Program In Question After Failed Stroke Trial

Companies announce a Phase III study in acute ischemic stroke patients failed to show an efficacy benefit over placebo.

Forest/Paion’s Desmoteplase Program In Question After Failed Stroke Trial

Companies announce a Phase III study in acute ischemic stroke patients failed to show an efficacy benefit over placebo.

Nuvelo To Consider In-Licensing Deals In Wake Of Negative Alfimeprase Data

The firm halts enrollment of trials of the thrombolytic pending further review by outside experts and monitoring board.

Related Content

Topics

UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel